Journal
TRANSPLANT INTERNATIONAL
Volume 26, Issue 7, Pages 662-672Publisher
WILEY
DOI: 10.1111/tri.12043
Keywords
alemtuzumab; anti-thymocyte globulin; Atgam; basiliximab; induction; induction immunosuppression; monoclonal; polyclonal; thymoglobulin; transplantation
Categories
Ask authors/readers for more resources
Currently available immunosuppressive agents can be classified into three categories: induction agents, maintenance therapy, and treatment for rejection. This review article will focus on induction immunosuppression. There are three antibodies which are used for induction therapy: the lymphocyte-depleting agents - anti-thymocyte globulin and alemtuzumab, and basiliximab which is nondepleting. Historically, immunosuppressant selection was solely based on efficacy for prevention of rejection. In the current era of transplantation, it is now common practice in the transplant community to select induction therapy on the basis of risk-benefit considerations for each patient. This article will focus on the efficacy of available induction agents and the selection of induction agent based on donor and recipient risk factors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available